Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Assets Average (2020 - 2025)

Historic Assets Average for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to $750.0 million.

  • Keros Therapeutics' Assets Average rose 4502.16% to $750.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $750.0 million, marking a year-over-year increase of 4502.16%. This contributed to the annual value of $493.0 million for FY2024, which is 4567.11% up from last year.
  • As of Q3 2025, Keros Therapeutics' Assets Average stood at $750.0 million, which was up 4502.16% from $770.9 million recorded in Q2 2025.
  • Keros Therapeutics' 5-year Assets Average high stood at $770.9 million for Q2 2025, and its period low was $230.9 million during Q2 2022.
  • Its 5-year average for Assets Average is $401.5 million, with a median of $345.6 million in 2023.
  • In the last 5 years, Keros Therapeutics' Assets Average soared by 63682.06% in 2021 and then plummeted by 785.89% in 2022.
  • Quarter analysis of 5 years shows Keros Therapeutics' Assets Average stood at $242.6 million in 2021, then grew by 15.28% to $279.7 million in 2022, then increased by 24.48% to $348.1 million in 2023, then soared by 71.65% to $597.6 million in 2024, then grew by 25.5% to $750.0 million in 2025.
  • Its Assets Average stands at $750.0 million for Q3 2025, versus $770.9 million for Q2 2025 and $700.2 million for Q1 2025.